Clinical Trials
20
Trial Phases
3 Phases
Drug Approvals
212
Drug Approvals
FLUBLOK trivalent recombinant influenza vaccine, Influenza haemagglutinin recombinant 135 mcg, 0.5 mL solution for injection syringe (446791)
- Product Name
- FLUBLOK trivalent recombinant influenza vaccine, Influenza haemagglutinin recombinant 135 mcg, 0.5 mL solution for injection syringe
- Approval Date
- May 9, 2025
Fluzone Inactivated Trivalent Influenza Vaccine (Split Virion) - Influenza virus haemagglutinin, 45 mcg/ 0.5 mL, suspension for injection, syringe (446170)
- Product Name
- Fluzone Inactivated Trivalent Influenza Vaccine (Split Virion)-Influenza virus haemagglutinin, 45 mcg/ 0.5 mL suspension for injection, syringe
- Approval Date
- May 9, 2025
XENPOZYME olipudase alfa 4mg powder for injection vial (423370)
- Product Name
- XENPOZYME olipudase alfa 4 mg powder for injection vial
- Approval Date
- May 3, 2024
BEYFORTUS nirsevimab 50mg in 0.5mL solution for injection prefilled syringe (397898)
- Product Name
- BEYFORTUS nirsevimab 50mg in 0.5mL solution for injection prefilled syringe
- Approval Date
- Nov 24, 2023
BEYFORTUS nirsevimab 100mg in 1mL solution for injection prefilled syringe (397899)
- Product Name
- BEYFORTUS nirsevimab 100mg in 1mL solution for injection prefilled syringe
- Approval Date
- Nov 24, 2023
XENPOZYME olipudase alfa 20mg powder for injection vial (394103)
- Product Name
- XENPOZYME olipudase alfa 20 mg powder for injection vial
- Approval Date
- Aug 24, 2023
Verorab rabies virus vaccine (inactivated) 3.25 IU powder for injection vial with diluent pre-filled syringe with attached needle (371727)
- Product Name
- Verorab rabies virus vaccine (inactivated) 3.25 IU powder for injection vial with diluent pre-filled syringe with attached needle
- Approval Date
- Oct 17, 2022
- Prev
- 1
- 2
- 3
- 4
- 5
- 21
- Next
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
News
Day One Biopharmaceuticals Appoints Michael Vasconcelles as Head of R&D to Drive Pipeline Expansion
Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company.
Pharmaceutical Industry Sees Wave of Board Appointments as Companies Strengthen Leadership
Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams.
Digital Health Technologies and AI Show Promise for Transforming Lysosomal Storage Disorder Care in Europe
A pioneering European initiative led by Professor Maurizio Scarpa explores integrating digital health innovations including AI, telemedicine, and connected care technologies into care pathways for Lysosomal Storage Disorders.
Takeda Spotlights Three Late-Stage Readouts as Potential "Inflection Point" Amid Vyvanse Generic Competition
Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition.
AbbVie and Galapagos Form $406 Million Alliance to Develop Novel Cystic Fibrosis Therapies
• AbbVie has partnered with Galapagos NV in a global alliance worth up to $406 million to discover and develop combination therapies targeting key mutations in cystic fibrosis patients. • The collaboration aims to develop oral drugs addressing F508del and G551D mutations in the CFTR protein, with plans to initiate Phase 1 clinical trials by the end of 2014. • This partnership joins other significant industry efforts to combat cystic fibrosis, including Pfizer's expanded six-year research program with the Cystic Fibrosis Foundation worth up to $58 million.